A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment

BACKGROUND: Therapeutic strategies targeting immune checkpoint proteins have led to significant responses in patients with various tumor types. The success of these studies has led to the development of various antibodies/inhibitors for the different checkpoint proteins involved in immune evasion of...

Descripción completa

Detalles Bibliográficos
Autores principales: Mediavilla-Varela, Melanie, Castro, Julio, Chiappori, Alberto, Noyes, David, Hernandez, Dalia C., Allard, Bertrand, Stagg, John, Antonia, Scott J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2017
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458644/
https://www.ncbi.nlm.nih.gov/pubmed/28582704
http://dx.doi.org/10.1016/j.neo.2017.02.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458644/
https://www.ncbi.nlm.nih.gov/pubmed/28582704
http://dx.doi.org/10.1016/j.neo.2017.02.004

Ejemplares similares